Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.

Registered dietitian Ayla Barmmer told The Post that about 15% of her patients taking GLP-1 medications have struggled to ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

A popular weight-loss jab has been approved to treat a common sleep disorder in Australia, after a new ruling by the medicine ...

After experiencing high growth in the U.S. telehealth scene, Hims is taking its personalized obesity treatments ...

Doctors have warned users of medicines such as Ozempic Wegovy and Mounjaro about an irreversible potential side effect ...

Obesity prevalence is rapidly increasing among older adults, posing significant health challenges and emphasizing the need ...